Recombinant Human Eotaxin Protein (His Tag)

Name: Recombinant Human Eotaxin Protein (His Tag)
Brand: Beta LifeScience
SKU: BLPSN-1774
Availability: InStock

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	His
Host Species	Human
Accession	P51671
Synonym	SCYA11
Background	CCL11 or chemokine (C-C motif) ligand 11 is a member of the chemokine (C-C motif) ligand family. Chemokin (C-C motif) ligand 11 is a member of the chemokine family. There are four members of the chemokine family: C-C kemokines, C kemokines, CXC kemokines and CX3C kemokines. The C-C kemokines have two cysteines nearby the amino terminus. There have been at least 27 distinct members of this subgroup reported for mammals, called C-C chemokine ligands (CCL)-1 to 28. Chemokines are a family of small chemotactic cytokines, or proteins secreted by cells. They share the same structure similarities such as small size, and the presence of four cysteine residues in conserved locations in order to form their 3-dimensional shape. Some of the chemokines are considered pro-inflammatory which can be induced to recruit cells of the immune system to a site of infection during an immune response, while others are considered homeostatic and are implied in controlling the migration of cells during normal processes of tissue maintenance and development. CCL11 is implicated in allergic responses through selectively recruiting eosinophils by inducing their chemotaxis. The effects of CCL11 are mediated by its binding to chemokine receptor. Increased CCL11 levels in blood plasma are associated with aging in mice.
Description	A DNA sequence encoding the human CCL11 (P51671) (Gly 24-Pro 97) was expressed, with a His tag at the N-terminus.
Source	E.coli
Predicted N Terminal	Met
AA Sequence	Gly 24-Pro 97
Molecular Weight	The recombinant human CCL11 consists of 93 a.a. and has a calculated molecular mass of 10.8 kDa. The apparent molecular mass of the protein is approximately 14 kDa in SDS-PAGE under reducing conditions.
Purity	>97% as determined by SDS-PAGE
Endotoxin	Please contact us for more information.
Bioactivity	Please contact us for detailed information
Formulation	Lyophilized from sterile PBS, 10% glycerol, pH 7.5.
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function	In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10610 OMIM: 601156 KEGG: hsa:6356 STRING: 9606.ENSP00000302234 UniGene: Hs.54460

Gene Functions References

These results suggest CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients PMID: 28634890
analyzed the genotypes of 6 tag SNPs in the CCL11 gene (rs1129844, rs17809012, rs1860183, rs1860184, rs4795898, and rs4795895) in a case control study. We found the GG genotype of rs4795895 was significantly associated with increased risk of lacunar stroke and the GA genotype of rs17809012 was associated with a significant increase in risk of LAA stroke PMID: 28873081
CCL11 promotor polymorphism is associated with increased risk for the development of schizophrenia in a Korean population. PMID: 29477870
Findings suggest that CCL11-CCR3 binding is involved in the progression of GBM. PMID: 27119233
There were no significant differences in GE area of infertile and fertile women. C-C motif chemokine 11 (P=0.048), TGFalpha (P=0.049), IFNgamma (P=0.033) and interleukin-1 alpha (P=0.047) were significantly elevated in uterine lavage from infertile women <35years compared to fertile but not in women 35years PMID: 27525354
eotaxin promotes proliferation in vascular smooth muscle cells and triggers oxidative stress in a NADPH oxidase dependent manner. PMID: 27681294
a receiver operating characteristic (ROC) curve analysis demonstrated CSF CCL11 accurately distinguished CTE subjects from non-athlete controls and AD subjects PMID: 28950005
These studies characterized serum and intestinal wall eotaxin-1 levels in various inflammatory bowel disease patients and to explore the effect of targeting eotaxin-1 by specific antibodies in dextran sodium sulfate-induced colitis model. PMID: 26874691
this study shows that expression of CCL11 is increased in eosinophilic myocarditis patients compared to chronic lymphocytic myocarditis patients PMID: 27621211
Review: eotaxins (CCL11, CCL24, and CCL26) play key role(s) during symptomatic inflammatory responses raised in response to allergic crisis of allergic asthma and atopic dermatitis PMID: 26861136
increased amounts released by neutrophils from fibromyalgia patients PMID: 26341115
Eotaxin measured on the day of birth is useful for identifying extremely low birth weight infants at risk of bronchopulmonary dysplasia/death. PMID: 26270578
The results of this study suggested that eotaxin-1 as a novel modifier of Alzheimer's disease age at onset and open potential avenues for therapy. PMID: 26324103
ANDV caused long-term elevated levels of eotaxin-1, IL-6, IL-8, IP-10, and VEGF-A that peaked 20-25 days after infection PMID: 26907493
The A allele in eotaxin 67 G/A polymorphism is associated with worse survival in CAD patients. PMID: 26491210
Findings demonstrate a link between CCL11 and primary Sjogren's syndrome disease activity and lymphoma. PMID: 26359802
Serum and urinary CCL11 were decreased in patients with prostate cancer compared with controls. PMID: 26306920
Results show the structure of CCL11 bound to the sulfated N-terminal region of its receptor CCR3 and show that intact CCR3 is sulfated and sulfation enhances receptor activity. PMID: 25450766
SF of BC OA displayed significantly higher concentrations for a number of proinflammatory cytokines [CXCL1, eotaxin, interferon (IFN)-gamma, interleukin (IL)-7, IL-8, IL-9, IL-12]. PMID: 25393692
Taken together, these findings indicate that inhibiting IL-4-induced eotaxin-1 expression by synephrine occurs primarily through the suppression of eosinophil recruitment, which is mediated by inhibiting STAT6 phosphorylation. PMID: 25111027
eotaxin-1 increases MMP-3 expression via the CCR3-ERK pathway, thereby promoting prostate cancer cell invasion and migration. PMID: 24604010
the CCL11 GG genotype is a significant risk factor for ischemic as well as hemorrhagic stroke. Further, the frequency of the GG genotype was observed to be higher in hemorrhagic stroke patients in comparison with ischemic stroke. PMID: 25237944
CCL11 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
thi is a study of the interaction between vCCI and eotaxin-1 (CCL11), a CC chemokine that is an important factor in the asthma response. PMID: 24482230
Cannabis use was found to increase CCL11 plasma levels and the effects were reversed when cannabis use ceases. PMID: 23820464
CCL11, CCL24, and CCL26 are increased in TB patients; hence, it seems that TB suppresses Th1 and the classic function of macrophages subsequently by inducing the chemokines' expression PMID: 24600981
CCL11, CCL24, and CCL26 has a role in the recruitment of extravillous trophoblast into decidual tissue and vessels. PMID: 23477905
CCL11 contributes to eosinophil recruitment in UC and that intestinal myeloid cells are a source of CCL11. PMID: 23904440
These data uncover a previously unknown role for NRF2 in regulating Eotaxin-1 expression and further the mechanistic understanding of this pathway in modulating inflammatory lung disease. PMID: 23061798
The impact of three single-nucleotide polymorphisms in eotaxin (SCYA11) gene promoter (-426C>T and -384A>G) and first exon (67G>A) and recently described hexanucleotide (GAAGGA)(n) 10.9 kb upstream on coronary atherosclerosis was investigated. PMID: 22773402
Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). PMID: 23059958
The Marfan syndrome patients with lowest mental quality of life and vitality scores had high levels of CCL11 cytokine. PMID: 23049769
Study found that the plasma concentration of eotaxin was associated with the clinical severity of chronic rhinosinusitis in Taiwanese patients. PMID: 22271279
The level of eotaxin expression and inflammatory cell count were measured in the material from nasal brushing in healthy controls and in patients with allergic rhinitis, asthma, and chronic obstructive pulmonary disease. PMID: 22846146
the eotaxin/CCL11-CCR3 axis is active in idiopathic retroperitoneal fibrosis (IRF) and may contribute to its pathogenesis; the TTCCAT haplotype within the CCL11 gene is significantly associated with IRF PMID: 23114905
Serum CCL17, IL-8, and eotaxin levels were significantly increased in eosinophilic subjects as compared to normal controls, but were similar between Churg-syndrome and hypereosinophilic syndrome. PMID: 22775568
Eotaxin-1 not only induces MMP-3 gene expression but also promotes MMP-3 protein secretion through G protein-coupled eotaxin-1 receptor activities. PMID: 22114952
Pretreated CCD-11Lu cells with noncytotoxic doses (0.1-10 muM) of CAPE inhibited the production of eotaxin under stimulation of IL-4 and tnf-alpha.CAPE pretreatment decreased the amount of pSTAT6 and STAT6 DNA binding complexes in nuclear extracts. PMID: 21601544
In this study, eotaxin-1 -384 A>G or 67 G>A genotypes were not associated with susceptibility to Nasal Polyposis. PMID: 21825098
Data show that expression levels of CCL11 and CCR3 mRNA in the lesional skin of ALCL were significantly higher than those in normal skin. PMID: 21406396
After corticosteroid therapy, the expressions of Eotaxin and Eotaxin-2 in mucosal epithelia of nasal polyps were significantly decreased. PMID: 19522186
Eotaxin induces proliferation of nonasthmatic airway smooth muscle cells and decreases their rate of apoptosis. PMID: 21368236
The expression of Eotaxin-1 and -2 in nasal polyposis and polyps was dramatically higher than in controls. PMID: 17438849
Corticosteroid treatment of nasal polyps reduced expression of CCL11. PMID: 17438850
Measurements of eotaxin-1 in exhaled breath condensate of asthma patients may provide a useful diagnostic tool for detecting and monitoring airway inflammation and disease severity. PMID: 20704746
Serum CCL18 level was significantly decreased in epithelial ovarian cancer patients with early stages compared to those with late stages. PMID: 19937162
elevated levels of eotaxin in children with stable asthma; correlation with eosinophilia PMID: 20444156
Eotaxin may up-regulate the expression of VCAM-1 in vessel endothelium and promote adhesion and migration of eosinophils, as a result, to lead to the recurrence of nasal polyps. PMID: 16874958
Serum CCL11 was increased in ulcerative colitis (UC) and less in Crohn's disease (CD), whereas CCL24 and CCL26 were increased only in UC. Colon expression of the CCL's was higher in UC vs. CD, and was induced by Th2 cytokines in colon epithelial cells. PMID: 21077277
SOCS1 and 3 may control chemotaxis and adhesion PMID: 20934424

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.